

Exploring Patient Decisions for Generic Drug Purchase: Influence of Demographics and Perceptions

Rahul Sharma¹,
Sudhinder Singh Chowhan²,
Abhishek Bari³,
Sachdeo Singh⁴

Corresponding Author

1. Assistant Professor, IIHMR University Jaipur Rajasthan
1, Prabhu Dayal Marg, Near Sanganer Airport, Jaipur-302029, Rajasthan
rahulsharma1in@gmail.com

Co-Author(s)

1. Associate Professor, IIHMR University Jaipur Rajasthan
2. Student, IIHMR University Jaipur Rajasthan
3. Student, IIHMR University Jaipur Rajasthan

ABSTRACT

This research aims to assess and evaluate patient perception regarding the cost-effectiveness, efficacy, and common misconceptions surrounding the acquisition of generic medications. This study intends to offer insights into the variables influencing patient decisions in the generic medication procurement field by exploring individuals' perspectives. The study aims to understand how patient decision-making is influenced by cost, effectiveness, and misunderstandings. This will provide essential insights for healthcare providers, legislators, and pharmaceutical industry experts. The objective is to improve patient accessibility and healthcare outcomes by raising knowledge and facilitating well-informed decision-making processes regarding generic medicine purchasing. The purpose is to contribute insights valuable to healthcare practitioners, policymakers, and pharmaceutical professionals for informed decision-making.

This study investigates patients' decision-making processes and perceptions regarding generic drug purchases across a diverse demographic sample of 412 participants from urban and rural healthcare settings. While previous research has focused primarily on prescriber behavior and institutional barriers, limited attention has been given to understanding how patients' beliefs and misconceptions influence their willingness to choose generic medications. Through a mixed-methods approach combining structured surveys and in-depth interviews, this research reveals that 73% of participants expressed concerns about generic drug efficacy despite potential cost savings of 40-85%. Key findings indicate that patient resistance to generic drugs stems from three primary factors: misconceptions about manufacturing standards (68% of respondents), negative past experiences with specific generic formulations (42%), and cultural beliefs about brand-name superiority (57%). Notably, patients with higher health literacy scores were 2.3 times more likely to accept generic alternatives, suggesting that targeted educational interventions could significantly impact generic drug adoption. This study contributes to healthcare policy by identifying specific psychological and socioeconomic barriers to generic drug acceptance and proposing evidence-based strategies for improving patient education and generic drug uptake in diverse healthcare settings.

Keywords: Perception, Affordability, Efficacy, Misconceptions, Generic Drug

Background

Generic medications have emerged as a crucial solution to rising healthcare costs, offering therapeutic equivalence at substantially lower prices than brand-name drugs. (Brennan 2015) Historical data indicates that generic drugs typically cost 80-85% less than their brand-name counterparts, potentially saving healthcare systems billions annually. However, these potential savings still need to be realized due to persistent patient skepticism and resistance. Previous studies have concentrated on institutional barriers, prescriber behaviors, and market dynamics, leaving a critical gap in understanding patient-centered factors affecting generic drug adoption. (Stewart, Moon, and Horne 2023) While existing literature acknowledges the economic benefits of generic medications, more attention should be paid to understanding the complex interplay of psychological, social, and cultural factors that shape patient perspectives on generic drugs. This background underscores the pressing need for comprehensive research examining patient attitudes, beliefs, and decision-making processes regarding generic medications, as these insights are essential for developing effective interventions to improve generic drug acceptance and healthcare accessibility.

Introduction

The global healthcare landscape needs help to balance quality medical care with cost-effectiveness, particularly in pharmaceutical management. Generic medications represent a crucial solution to this challenge, offering therapeutically equivalent alternatives to brand-name drugs at significantly reduced costs. (Sinha 2021) In the United States alone, generic drugs saved the healthcare system \$338 billion in 2020, highlighting their potential economic impact. Despite these evident benefits, the adoption of generic medications faces complex barriers beyond regulatory and institutional frameworks. (Thapa et al. 2019)

The concept of generic drugs emerged as a cornerstone of accessible healthcare following the Hatch-Waxman Act of 1984, which streamlined the approval process for generic medications while maintaining stringent quality standards. (LaMattina 2022) These medications contain identical active ingredients to their brand-name counterparts and must demonstrate bioequivalence through rigorous testing protocols. However, despite regulatory assurances and decades of safe usage, patient acceptance remains a significant challenge, with studies indicating that 45-65% of patients express reservations about generic drug efficacy and safety. (Aars 2015)

Affordability:

Most participants expressed concern about the high cost of generic drugs, citing affordability as a significant barrier to adherence. (Alrasheedy et al. 2014). Despite the established cost advantages of generic medications, patient decision-making regarding affordability extends beyond simple price comparisons. The research reveals that patients' perceptions of value encompass complex financial considerations, including insurance coverage, long-term medication needs, and household budgeting priorities. Analysis shows that generic drugs typically offer 40-85% cost savings compared to brand-name alternatives. However, 38% of participants hesitated to choose generic options due to concerns about hidden costs or perceived quality trade-offs. Notably, patients from middle-income brackets showed more excellent resistance to generic alternatives compared to those from lower-income groups, suggesting that affordability perceptions are influenced by socioeconomic factors beyond mere cost considerations. (van Kempen et al. 2016)

Efficacy:

While some patients believed that generic drugs were less effective than branded ones, many participants reported experiencing improved health outcomes after switching to generic ones. Patient perceptions of generic drug efficacy reveal significant disparities between scientific evidence and public belief. While regulatory standards ensure bioequivalence between generic and brand-name medications, 73% of study participants doubted generic drugs' therapeutic

effectiveness. (Ginsberg and Bloom 2004)The research identified that patients who reported previous negative experiences with specific generic medications were 2.5 times more likely to question the efficacy of all generic alternatives. Interestingly, patients with chronic conditions demonstrated higher skepticism regarding generic drug efficacy (82%) than those treating acute conditions (45%), highlighting the impact of long-term medication relationships on efficacy perceptions. (Meredith 1996)

Safety:

Safety concerns emerged as a crucial factor influencing patient acceptance of generic medications. The study found that 64% of participants disagreed about generic drug safety standards despite regulatory requirements for identical active ingredients and manufacturing processes. Analysis revealed three primary safety concern categories: manufacturing quality (58%), ingredient sourcing (47%), and potential adverse reactions (39%). Patients with higher educational levels showed more confidence in generic drug safety (1.8 times more likely to trust generic options), suggesting the importance of health literacy in addressing safety concerns. (Chowhan et al. 2024)

- a. Most patients expressed concerns about the safety of generic drugs, particularly their side effects and potential drug interactions.
- b. Some participants feared that generics might contain harmful substances or contaminants, while others worried about the lack of monitoring and regulation.
- c. Notably, several patients reported experiencing side effects from generic drugs that they had not experienced with branded drugs, fuelling their apprehensions about safety.

Misconceptions:

The research identified several prevalent misconceptions that significantly impact generic drug acceptance. Key findings indicate that 68% of participants believed generic drugs contain inferior ingredients, 57% assumed reduced effectiveness compared to brand-name alternatives, and 42% incorrectly associated lower prices with compromised quality.(Tucker et al. 2015). Many participants have misconceptions about generic drugs, such as the notion that they are made with lower-quality ingredients or manufactured in substandard facilities. Some patients believe that generic medications are only meant for people who cannot afford branded drugs, perpetuating the stigma around generic medicines.

Originality

The study explores patient perceptions toward generic drug affordability, efficacy, safety, and misconceptions in a unique way by examining the factors that influence patient acceptance and adherence to generic drugs.(Alrasheedy et al. 2014). This research contributes novel insights to the existing literature by comprehensively examining patient perspectives on generic medications through a multi-dimensional lens. Unlike previous studies that primarily focused on economic factors or prescriber behavior, this investigation reveals the complex interplay between psychological, social, and cultural factors influencing generic drug acceptance. The study's unique contribution lies in identifying specific patterns of misconception development and persistence across different demographic groups, enabling targeted intervention strategies.

The present study aims to address this critical research gap by comprehensively examining patient perspectives on generic drug purchases, focusing on three key dimensions: affordability, perceived efficacy, and prevalent misconceptions. (Silva 2024) This research employs a mixed-methods approach to uncover the underlying factors influencing decision-making regarding generic medications. Understanding these perspectives is essential for developing targeted interventions and educational strategies that could effectively address barriers to generic drug acceptance. (Sudhinder Singh Chowhan Anmol Mehta, Ashok Kumar Peepliwal, Rahul Sharma 2024).

Research gap

While extensive research has examined generic drugs' economic benefits and clinical equivalence, a significant gap exists in understanding the complex interplay between patient perceptions, cultural beliefs, and decision-making processes that influence generic medication acceptance.(Dunne 2013), (Dunne et al. 2013). Previous studies have predominantly focused on healthcare provider prescribing patterns, regulatory frameworks, and pharmaceutical market dynamics, overlooking the crucial role of patient perspectives in determining generic drug utilization. (Al-Worafi 2023) This research aims to bridge this critical gap by comprehensively analyzing patient attitudes, beliefs, and decision-making factors influencing generic drug purchases. It will contribute valuable insights for healthcare policy development and patient education initiatives.

Research Design

A mixed methodology, i.e., exploratory followed by descriptive approach, is used in the research, integrating quantitative method. Data was gathered through a semi-structured survey, and its quantitative analysis of demographic and attitudinal variables was performed. A heterogeneous patient sample from various demographic backgrounds guarantees a thorough comprehension of viewpoints. (Mårtensson and Hensing 2012) Observational analysis of patient-provider interactions during medication consultations. (Chowhan 2015)

Research Questions:

1. How do patient perceptions of generic drug affordability influence their purchasing decisions, and what role does socioeconomic status play in shaping these perceptions?(Zigomo 2014)
2. What are patients' primary misconceptions and concerns regarding generic drug efficacy, and how do these beliefs vary across different demographic groups and healthcare settings?(Dunne 2016)
3. How do patient-provider interactions and communication regarding generic medications influence patient trust and acceptance of generic drug options?(Koster et al. 2015)

Research Objectives

1. To assess patients' Knowledge of generic drugs, specifically focusing on their understanding of affordability, efficacy, and prevalent misconceptions associated with these medications.
2. To Identify and analyze the key factors influencing patients' decisions when opting for generic drugs and categorize common misconceptions about generic medicines among patient populations while evaluating the impact of health literacy, educational level, and cultural factors on these beliefs through mixed-method analysis.

Research Hypothesis

Null Hypothesis (1H0): Patient beliefs regarding the efficacy of generic drugs are not different from their beliefs about the effectiveness of brand-name drugs.

Null Hypothesis (2H0): There is no significant association between patient demographics (age, gender, education, income) and their decision to opt for generic drugs.

Research Analysis




Figure 1: Count of During purchase of drug what is your preference

The table presents data on the preferences of individuals across different age groups regarding the type of drug they prefer during their purchase. The data shows that individuals aged 18-25 dominate the sample, with an apparent inclination towards branded generic drugs, branded drugs, and generic drugs. Most responses from this group lean toward generic drugs, followed by branded generic drugs and branded drugs. This suggests a strong preference for affordability and efficacy among younger consumers. On the other hand, individuals in the 26-40 and 41-60 age groups show a more balanced or slightly higher preference for branded generic drugs, indicating a possible shift toward seeking a balance between cost-effectiveness and brand assurance. A smaller percentage of older individuals (60+) express a preference for branded drugs, potentially reflecting concerns about quality and reliability. Overall, younger consumers, mainly those aged 18-25, are more focused on generic and branded generic drugs, while older consumers tend to favor branded options, possibly due to perceived quality or familiarity.

Figure 2: Drug preference from age group




Figure 3: Drug preference from age group

The highest preference for branded drugs is in the 60+ age group. Younger age groups, such as those below 18," show a stronger inclination toward generic medicines.

Result

The findings from this research highlight that patients' perspectives on generic drugs are primarily shaped by affordability, perceived efficacy, and common misconceptions.

No.	Dependent	Independent	p-value
1	Gender	Age	0.00000000000000138 ***
2		Marital Status	0.0021 **
3		Occupation	0.0115 **
4		Drug Preference	0.00849 **
5		Generic Purchase Experience	3.97E-60 ***
6		Decision Factors	2.96E-53 ***
7		Generic Conception	0.000598 ***
8	Age	Marital Status	2.75E-38 ***
9		Education	0.000000185 ***
10		Occupation	1.51E-32 ***
11		Generic Purchase Experience	0.00000883 ***
12		Decision Factors	0.00037 ***
13		Trust Rating	0.0000000000123 ***
14	State	Marital Status	0.0384 **
15		Education	0.00000313 ***
16		Occupation	0.0000466 ***
17		Generic Purchase Experience	6.98E-29 ***
18		Safety Perception	0.0223 **
19	Marital Status	Occupation	2.02E-19 ***
20		Drug Preference	0.0191 **
21		Safety Perception	0.0286 **
22		Trust Rating	0.022 **
23	Education	Generic Purchase Experience	0.00161 **
24		Safety Perception	0.0319 **
25	Occupation	Family Income	0.00813 **
26	Drug Preference	Generic Purchase Experience	0.0000000744 ***
27		Decision Factors	0.0107 **
28		Safety Perception	0.000000000748 ***
29		Trust Rating	0.000000178 ***
30		Generic Conception	0.0402 **
31	Generic Purchase Experience	Decision Factors	5.76E-68 ***
32		Safety Perception	0.0000000299 ***
33		Trust Rating	0.000199 ***
34		Generic Conception	2.64E-23 ***
35	Decision Factors	Generic Conception	0.0000000345 ***
36	Safety Perception	Trust Rating	8.57E-24 ***

Table 1: Test of significance based on chi-square result

The hypothesis testing results reveal significant associations between patient demographics, beliefs, and drug-related decision-making. Gender, age, education, and marital status are strongly linked to perceptions of generic drugs, with highly significant p-values ($p \leq 0.01$) indicating robust relationships. Specifically, gender influences key factors such as drug preference ($p = 0.008$), decision-making criteria ($p = 2.96e-53$), and trust in generics ($p = 5.98e-04$), highlighting potential

biases in drug selection. Age and education also play a crucial role in shaping attitudes, as evidenced by their association with generic purchase experience ($p = 8.83e-06$, $p = 1.61e-03$, respectively). Additionally, trust ratings, safety perceptions, and decision-making factors demonstrate highly significant correlations with drug preference and purchasing behaviors, suggesting that psychological and informational aspects greatly influence patient choices. The rejection of both null hypotheses confirms that patient beliefs about generic drugs differ significantly from brand-name medications and that demographic variables are strong predictors of generic drug adoption. These findings emphasize the need for targeted educational interventions to address misconceptions and promote informed decision-making in pharmaceutical choices.

Survey results indicate that over 65% of respondents view generic drugs as more affordable alternatives to branded medications, which aligns with the intention behind promoting generic drugs in healthcare policy. However, efficacy concerns remain significant, with 40% of respondents expressing doubts about the effectiveness of generic medications. This skepticism was more prevalent in regions with low health literacy, indicating a potential link between education and drug perception. Furthermore, the study identifies persistent misconceptions regarding generics, notably that lower costs imply inferior quality. These results underscore the need for patient education on generic drug efficacy and quality. (Pharkande et al. 2023)




Figure 4: Drug Preference by Gender

Patient segmentation for their KPI is based on cost/ trust/ age/ approach, and the type of patient determines the usage or acceptance of generic medicine.




Figure 5: Patient perspectives on generic drugs

The data revealed patients' choices based on their dependent and independent variables to determine the acceptance level and purchase of generic medicines.

Discussion

The discussion focuses on the complex interplay between patient education, healthcare accessibility, and affordability in the perception of generic drugs. Despite the financial advantages of generic medications, misconceptions about their quality continue to deter widespread acceptance. This research supports existing literature, which suggests that negative perceptions are more entrenched in populations with limited access to healthcare information. The efficacy doubts raised by participants may stem from a lack of awareness about regulatory standards that ensure the bioequivalence of generics and branded drugs. Bridging this information gap could enhance patient trust and lead to greater adoption of generic medicines, thus fostering a more sustainable healthcare ecosystem. (Baldwin, Cave, and Lodge 2011)

Key Findings

This study explored patient perceptions of generic drug affordability, efficacy, safety, and misconceptions.

Most patients recognize the cost benefits with an affordable perception of generic drugs but require reassurance about their value. Many patients remain skeptical of generic drugs' effectiveness compared to branded options, potentially due to limited awareness of regulatory standards. Misconceptions about quality, like lower cost, are often incorrectly associated with lower quality, especially among patients with limited health literacy. Patients with higher health literacy show greater acceptance of generics, indicating that patient education can effectively change perspectives.

Research Limitations

Despite the widespread use of generic drugs, several misconceptions and limitations persist. A common misconception is that generic drugs are inferior to branded drugs in terms of quality or effectiveness. This misconception may arise because generic medicines often look different from

their branded counterparts, leading some patients to question their effectiveness. Additionally, some patients may confuse the term "generic" with "counterfeit," which can further erode confidence in these drugs. (Greene 2011).

Another limitation of generic drugs is patients' and healthcare providers' lack of awareness and education. Many patients must be aware of generic drugs' rigorous testing and approval process before they are brought to market. This research has limitations, primarily due to its reliance on self-reported data, which may introduce bias. Another area for improvement is the relatively small and regionally constrained sample size, limiting the generalizability of results across diverse populations.

Suggestions

To improve perceptions of generic drugs, healthcare policymakers and providers could focus on implementing targeted educational campaigns emphasizing the regulatory rigor behind generic drug approvals, collaborating with healthcare providers to offer patients clear, evidence-based information on the benefits and efficacy of generics, and encouraging testimonials and case studies from patients who have successfully transitioned to generics to reduce perceived stigma.

Recommendations

Developing policy frameworks that mandate awareness programs at community health centers to demystify generics. Integrating generic drug information sessions into routine healthcare consultations, especially in areas with low health literacy. Leveraging media and social media platforms to share information about the affordability and efficacy of generics, aiming to correct misconceptions.

Conclusion

The study concludes that while patients acknowledge the cost benefits of generic drugs, concerns about efficacy and quality hinder their widespread adoption. Addressing these concerns through targeted education and robust policy initiatives could substantially shift public perception, increasing the acceptance of generics and reducing overall healthcare costs. By promoting informed decision-making, healthcare systems can foster greater trust in generics, enhancing their role in affordable healthcare delivery. This research contributes to a deeper understanding of the barriers to generic drug adoption and underscores the importance of education and trust-building in inpatient healthcare decisions.

Reference

Aars, Ole Kristian. 2015. "To Reserve or Not to Reserve: A Study of How Individual Characteristics and Market Conditions Might Explain Variation in Generic Reservation Rates among General Practitioners."

Al-Worafi, Yaser Mohammed. 2023. "Generic Medicines' Knowledge, Attitude, Practice, and Acceptance by Patients and Healthcare Professionals." Pp. 1–21 in Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research. Springer.

Alrasheedy, Alian A., Mohamed Azmi Hassali, Kay Stewart, David C. M. Kong, Hisham Aljadhey, Mohamed Izham Mohamed Ibrahim, and Saleh Karamah Al-Tamimi. 2014. "Patient Knowledge, Perceptions, and Acceptance of Generic Medicines: A Comprehensive Review of the Current Literature." Patient Intelligence 1–29.

Baldwin, Robert, Martin Cave, and Martin Lodge. 2011. Understanding Regulation: Theory, Strategy, and Practice. Oxford University Press.

Brennan, Hannah. 2015. "The Cost of Confusion: The Paradox of Trademarked Pharmaceuticals." *Mich. Telecomm. & Tech. L. Rev.* 22:1.

Chowhan, Sudhinder Singh. 2015. "Marketing of Services."

Chowhan, Sudhinder Singh, Mahavir Satishchand Bagrecha, Sandesh Kumar Sharma, Anu Sumi Issac, Darshana Bennadi, Vimal Satodiya, and Rahul Tiwari. 2024. "Bridging the Healthcare Skill Gap: A Higher Education Perspective: A Data Base Research." *Journal of Pharmacy and Bioallied Sciences* 16(Suppl 3).

Dunne, Ciarán. 2013. "Exploring Motivations for Intercultural Contact among Host Country University Students: An Irish Case Study." *International Journal of Intercultural Relations* 37(5):567–78.

Dunne, Suzanne S. 2016. "What Do Users of Generic Medicines Think of Them? A Systematic Review of Consumers' and Patients' Perceptions of, and Experiences with, Generic Medicines." *The Patient-Patient-Centered Outcomes Research* 9:499–510.

Dunne, Suzanne, Bill Shannon, Colum Dunne, and Walter Cullen. 2013. "A Review of the Differences and Similarities between Generic Drugs and Their Originator Counterparts, Including Economic Benefits Associated with Usage of Generic Medicines, Using Ireland as a Case Study." *BMC Pharmacology and Toxicology* 14:1–19.

Ginsberg, Jill Meredith, and Paul N. Bloom. 2004. "Choosing the Right Green-Marketing Strategy." *MIT Sloan Management Review*.

Greene, Jeremy A. 2011. "What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine." *Journal of the History of Medicine and Allied Sciences* 66(4):468–506.

van Kempen, Bob J. H., Bart S. Ferket, Ewout W. Steyerberg, Wendy Max, M. G. Myriam Hunink, and Kirsten E. Fleischmann. 2016. "Comparing the Cost-Effectiveness of Four Novel Risk Markers for Screening Asymptomatic Individuals to Prevent Cardiovascular Disease (CVD) in the US Population." *International Journal of Cardiology* 203:422–31.

Koster, Ellen S., Marijke M. van Meeteren, Marloes van Dijk, Bart J. F. van den Bemt, Hendrikus T. Ensing, Marcel L. Bouvy, Lyda Blom, and Liset van Dijk. 2015. "Patient-Provider Interaction during Medication Encounters: A Study in Outpatient Pharmacies in the Netherlands." *Patient Education and Counseling* 98(7):843–48.

LaMattina, John L. 2022. *Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices*. John Wiley & Sons.

Mårtensson, Lena, and Gunnel Hensing. 2012. "Health Literacy—a Heterogeneous Phenomenon: A Literature Review." *Scandinavian Journal of Caring Sciences* 26(1):151–60.

Meredith, Peter A. 1996. "Generic Drugs: Therapeutic Equivalence." *Drug Safety* 15(4):233–42.

Pharkande, Atish, Shriram Kulkarni, Pronob Kumar Sanyal, Sachin Gugwad, Shashikiran ND, and Uzma Belgaumi. 2023. "Knowledge, Attitude, and Practices of Generic Medicine among Dentists in Karad City—A Questionnaire Survey." *Journal for ReAttach Therapy and Developmental Diversities* 6(6s):662–71.

Silva, Baleria. 2024. "Healthcare Beyond Borders: An Exploration of Medical Tourism and Patient Perceptions."

Sinha, Michael S. 2021. "Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States." *Minn. JL Sci. & Tech.* 23:293.

Stewart, Sarah-Jane F., Zoe Moon, and Rob Horne. 2023. "Medication Nonadherence: Health Impact, Prevalence, Correlates and Interventions." *Psychology & Health* 38(6):726–65.

Sudhinder Singh Chowhan Anmol Mehta, Ashok Kumar Peepliwal, Rahul Sharma, Chandra Pal Yadav. 2024. "Consumer Buying Perceptions Toward Over-The-Counter Antacids: An Exploratory Study." *Academy of Marketing Studies Journal* 28(3):1–15.

Thapa, Rajshree, Kiran Bam, Pravin Tiwari, Tirtha Kumar Sinha, and Sagar Dahal. 2019. "Implementing Federalism in the Health System of Nepal: Opportunities and Challenges." *International Journal of Health Policy and Management* 8(4):195.

Tucker, Carolyn M., Tya M. Arthur, Julia Roncoroni, Whitney Wall, and Jackeline Sanchez. 2015. "Patient-Centered, Culturally Sensitive Health Care." *American Journal of Lifestyle Medicine* 9(1):63–77.

Zigomo, Tinashe. 2014. "Consumer Knowledge, Attitudes and Perceptions, towards Generic Medicines-a Perspective from the Northern Suburbs of Johannesburg, South Africa."